HK Stock MarketDetailed Quotes

02373 BEAUTYFARM MED

Watchlist

17.280
-0.020-0.12%

Not Open Dec 13 16:08 CST

4.07BMarket Cap16.96P/E (TTM)

BEAUTYFARM MED Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(FY)Dec 31, 2019

Turnover

9.72%1.14B

31.16%2.15B

41.20%1.04B

-8.16%1.64B

-12.25%734.32M

18.46%1.78B

--836.83M

7.02%1.5B

--1.4B

Operating income

9.72%1.14B

31.16%2.15B

41.20%1.04B

-8.16%1.64B

-12.25%734.32M

18.46%1.78B

836.83M

7.02%1.5B

1.4B

Cost of sales

-8.01%-603.49M

-27.29%-1.17B

-32.95%-558.76M

3.10%-917.57M

6.16%-420.29M

-17.89%-946.95M

---447.88M

-15.34%-803.27M

---696.41M

Operating expenses

-8.01%-603.49M

-27.29%-1.17B

-32.95%-558.76M

3.10%-917.57M

6.16%-420.29M

-17.89%-946.95M

-447.88M

-15.34%-803.27M

-696.41M

Gross profit

11.73%534.2M

36.12%977.1M

52.25%478.11M

-13.91%717.84M

-19.26%314.03M

19.11%833.79M

388.95M

-1.17%700.02M

708.34M

Selling expenses

-13.65%-189.7M

-31.66%-378.17M

-38.82%-166.92M

4.09%-287.23M

7.75%-120.24M

-10.70%-299.46M

---130.34M

2.68%-270.52M

---277.97M

Administrative expenses

-9.21%-181.11M

-7.76%-318.35M

0.85%-165.84M

-8.44%-295.43M

-26.87%-167.26M

-21.60%-272.45M

---131.84M

5.61%-224.06M

---237.38M

Research and development expenses

5.37%-16.26M

-9.25%-34.07M

-14.62%-17.18M

-72.98%-31.19M

-93.42%-14.99M

-42.30%-18.03M

---7.75M

-38.59%-12.67M

---9.14M

Impairment and provision

19.11%-127K

-413.55%-796K

-168.26%-157K

88.13%-155K

141.82%230K

-164.81%-1.31M

---550K

-55.92%2.02M

--4.57M

-Other impairment is provision

19.11%-127K

-413.55%-796K

-168.26%-157K

88.13%-155K

141.82%230K

-164.81%-1.31M

---550K

-55.92%2.02M

--4.57M

Special items of operating profit

-41.49%16.07M

-5.54%45.58M

8.65%27.46M

35.93%48.25M

23.15%25.28M

91.53%35.5M

--20.52M

-1.17%18.53M

--18.75M

Operating profit

4.89%163.07M

91.52%291.29M

319.65%155.47M

-45.30%152.09M

-73.35%37.05M

30.33%278.04M

139M

2.97%213.33M

207.18M

Financing income

14.48%11.77M

605.79%21.84M

890.56%10.28M

141.15%3.09M

71.29%1.04M

13.14%1.28M

--606K

33.10%1.13M

--852K

Financing cost

-16.74%-14.35M

-0.40%-24.81M

-2.07%-12.29M

-2.05%-24.71M

2.27%-12.05M

6.60%-24.22M

---12.33M

8.26%-25.93M

---28.26M

Share of profits of associates

----

---51K

----

Earning before tax

4.58%160.49M

120.94%288.27M

489.31%153.46M

-48.85%130.48M

-79.54%26.04M

35.31%255.1M

127.28M

4.88%188.53M

179.76M

Tax

-6.45%-34.42M

-191.48%-58.13M

-422.32%-32.34M

57.35%-19.94M

72.08%-6.19M

-28.66%-46.76M

---22.18M

-12.39%-36.35M

---32.34M

After-tax profit from continuing operations

4.08%126.07M

108.21%230.14M

510.21%121.12M

-46.95%110.53M

-81.12%19.85M

36.90%208.34M

105.11M

3.23%152.19M

147.42M

Earning after tax

4.08%126.07M

108.21%230.14M

510.21%121.12M

-46.95%110.53M

-81.12%19.85M

36.90%208.34M

105.11M

3.23%152.19M

147.42M

Minority profit

14.60%10.65M

95.10%14.48M

96.57%9.29M

-50.07%7.42M

-42.08%4.73M

1,112.56%14.87M

--8.16M

-82.72%1.23M

--7.09M

Profit attributable to shareholders

3.21%115.42M

109.15%215.66M

639.47%111.83M

-46.71%103.11M

-84.40%15.12M

28.16%193.48M

96.95M

7.58%150.96M

140.33M

Basic earnings per share

2.04%0.5

80.77%0.94

512.50%0.49

-46.39%0.52

-91.75%0.08

-35.76%0.97

0.97

7.09%1.51

1.41

Diluted earnings per share

2.04%0.5

80.77%0.94

512.50%0.49

-46.39%0.52

-91.75%0.08

-35.76%0.97

0.97

7.09%1.51

1.41

Currency Unit

CNY

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

PricewaterhouseCoopers

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(FY)Dec 31, 2019
Turnover	9.72%1.14B	31.16%2.15B	41.20%1.04B	-8.16%1.64B	-12.25%734.32M	18.46%1.78B	--836.83M	7.02%1.5B	--1.4B
Operating income	9.72%1.14B	31.16%2.15B	41.20%1.04B	-8.16%1.64B	-12.25%734.32M	18.46%1.78B	836.83M	7.02%1.5B	1.4B
Cost of sales	-8.01%-603.49M	-27.29%-1.17B	-32.95%-558.76M	3.10%-917.57M	6.16%-420.29M	-17.89%-946.95M	---447.88M	-15.34%-803.27M	---696.41M
Operating expenses	-8.01%-603.49M	-27.29%-1.17B	-32.95%-558.76M	3.10%-917.57M	6.16%-420.29M	-17.89%-946.95M	-447.88M	-15.34%-803.27M	-696.41M
Gross profit	11.73%534.2M	36.12%977.1M	52.25%478.11M	-13.91%717.84M	-19.26%314.03M	19.11%833.79M	388.95M	-1.17%700.02M	708.34M
Selling expenses	-13.65%-189.7M	-31.66%-378.17M	-38.82%-166.92M	4.09%-287.23M	7.75%-120.24M	-10.70%-299.46M	---130.34M	2.68%-270.52M	---277.97M
Administrative expenses	-9.21%-181.11M	-7.76%-318.35M	0.85%-165.84M	-8.44%-295.43M	-26.87%-167.26M	-21.60%-272.45M	---131.84M	5.61%-224.06M	---237.38M
Research and development expenses	5.37%-16.26M	-9.25%-34.07M	-14.62%-17.18M	-72.98%-31.19M	-93.42%-14.99M	-42.30%-18.03M	---7.75M	-38.59%-12.67M	---9.14M
Impairment and provision	19.11%-127K	-413.55%-796K	-168.26%-157K	88.13%-155K	141.82%230K	-164.81%-1.31M	---550K	-55.92%2.02M	--4.57M
-Other impairment is provision	19.11%-127K	-413.55%-796K	-168.26%-157K	88.13%-155K	141.82%230K	-164.81%-1.31M	---550K	-55.92%2.02M	--4.57M
Special items of operating profit	-41.49%16.07M	-5.54%45.58M	8.65%27.46M	35.93%48.25M	23.15%25.28M	91.53%35.5M	--20.52M	-1.17%18.53M	--18.75M
Operating profit	4.89%163.07M	91.52%291.29M	319.65%155.47M	-45.30%152.09M	-73.35%37.05M	30.33%278.04M	139M	2.97%213.33M	207.18M
Financing income	14.48%11.77M	605.79%21.84M	890.56%10.28M	141.15%3.09M	71.29%1.04M	13.14%1.28M	--606K	33.10%1.13M	--852K
Financing cost	-16.74%-14.35M	-0.40%-24.81M	-2.07%-12.29M	-2.05%-24.71M	2.27%-12.05M	6.60%-24.22M	---12.33M	8.26%-25.93M	---28.26M
Share of profits of associates	----	---51K	----	----	----	----	----	----	----
Earning before tax	4.58%160.49M	120.94%288.27M	489.31%153.46M	-48.85%130.48M	-79.54%26.04M	35.31%255.1M	127.28M	4.88%188.53M	179.76M
Tax	-6.45%-34.42M	-191.48%-58.13M	-422.32%-32.34M	57.35%-19.94M	72.08%-6.19M	-28.66%-46.76M	---22.18M	-12.39%-36.35M	---32.34M
After-tax profit from continuing operations	4.08%126.07M	108.21%230.14M	510.21%121.12M	-46.95%110.53M	-81.12%19.85M	36.90%208.34M	105.11M	3.23%152.19M	147.42M
Earning after tax	4.08%126.07M	108.21%230.14M	510.21%121.12M	-46.95%110.53M	-81.12%19.85M	36.90%208.34M	105.11M	3.23%152.19M	147.42M
Minority profit	14.60%10.65M	95.10%14.48M	96.57%9.29M	-50.07%7.42M	-42.08%4.73M	1,112.56%14.87M	--8.16M	-82.72%1.23M	--7.09M
Profit attributable to shareholders	3.21%115.42M	109.15%215.66M	639.47%111.83M	-46.71%103.11M	-84.40%15.12M	28.16%193.48M	96.95M	7.58%150.96M	140.33M
Basic earnings per share	2.04%0.5	80.77%0.94	512.50%0.49	-46.39%0.52	-91.75%0.08	-35.76%0.97	0.97	7.09%1.51	1.41
Diluted earnings per share	2.04%0.5	80.77%0.94	512.50%0.49	-46.39%0.52	-91.75%0.08	-35.76%0.97	0.97	7.09%1.51	1.41
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion
Auditor	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers	PricewaterhouseCoopers

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

Investment Theme

Aesthetic Medicine

Intraday-2.44%

02373 BEAUTYFARM MED

BEAUTYFARM MED Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow